Research & Development
Brown University researchers developing serum-based tool for antidepressant monitoring
The technique simplifies and automates the monitoring of antidepressant drugs in human serum samples, addressing a biomedical need. The method has the potential to be translated to clinical settings, the authors wrote.
February 14, 2023
Measuring lithium from a fingertip
The sensor has the potential to enable patients to take the right amount of lithium to alleviate the symptoms of bipolar disorder and depression, the scientists said in a presentation at the American Chemical Society (ACS) fall meeting on Sunday.
August 22, 2022
Pharmacogenomic testing for better depression treatment
In the study, the patients being treated for major depressive disorder (MDD) who received pharmacogenomics testing also experienced better depression outcomes soon after they were tested.
July 13, 2022
Mynd launches new division to research depression biomarker
The new division's focus will be to evaluate a proprietary biomarker called Mynd Anti-inflammatory Peptide (MAP) in clinical trials for quantitatively diagnosing and monitoring depression in response to treatment for major depressive disorder and treatment-resistant depression.
October 6, 2021
Neurofilament light blood test shows concussion damage in study of veterans
Sponsored by grant funding from the U.S. Department of Defense (DOD) Chronic Effects of Neurotrauma Consortium (CENC), the study evaluated levels of the protein NfL in blood tests and how they correlated with concussion in 195 military veterans. Researchers found higher levels in veterans with a history of three or more concussions compared to those who had not had mTBI. In addition, high NfL was associated with more severe symptoms such as post-traumatic stress disorder (PTSD) and depression.
May 27, 2020
Myriad Genetics touts results from depression studies
The findings from four clinical trials, published April 17 in Pharmacogenomics, showed that GeneSight helped guide the appropriate clinical care of 1,556 patients with MDD and at least one prior antidepressant medication failure. With GeneSight, the patients experienced significantly better remission, response, and symptom improvement. Overall remission improved 49% (p = 0.001), response improved by 40% (p < 0.01), and symptoms improved by 43% (p = 0.019), all of which were statistically significant.
April 21, 2020
NIH-funded studies aim to get to the bottom of depression, suicide
The NIMH has jointly awarded a $3.6 million grant to investigate the potential for a blood test for suicide risk to researchers at the Van Andel Institute in Grand Rapids, MI; Pine Rest Christian Mental Health Services, also of Grand Rapids; and Columbia University in New York City. The grant money will be used over five years to study inflammatory mechanisms associated with suicide risk, based on research by Dr. Lena Brundin, PhD (Van Andel); Dr. Eric Achtyes (Pine Rest); and Dr. J. John Mann (Columbia).
August 28, 2019
Myriad Genetics depression test hits Kroger pharmacies
Patients with depression may cycle through a range of antidepressant drugs before they find one that works for them. GeneSight tests for 12 genes that can affect the efficacy of 56 different drugs used to treat the condition, with the goal of guiding patients to a therapy that is more likely to work based on their personal genetic makeup.
July 9, 2019
Failed study leaves CRP test hanging as biomarker in bipolar depression
The results leave the potential role of CRP as a biomarker up in the air. They also highlight the broader challenges in developing biomarkers and personalized treatments in the field of psychiatry.
May 7, 2019
Page 1 of 1